Replies to post #13765 on Intellipharmaceutics International Inc. (IPCI)

[wimuskyfisherman]

Mopar-

I agree with you on the cash situation. They are getting by. I think the additional Focalin XR doses will get them close to breaking even. My estimate is $10M per year on all doses but the 5 mg- which hopefully will be one of the next approved dosages- will be a big runner and account for much of the additional revenue.

Now regarding Rexista- I expect the NDA to be filed on schedule in Q2 2016. I am not convinced we will see a partner at that time as they may continue to hold out for a better deal. It would not surprise me to see a partner on Rexista w/PODRAS or Regabatin though. Those developments will require extensive clinical trial and a partner will be needed to fund.

And as always, these are just my opinion...